Investigate / BMY
Understand BRISTOL MYERS SQUIBB CO
Can new pipeline and licensed assets add enough value to offset pricing pressure and generic erosion across the established portfolio?
Snapshot reviewed 2026-10-02. Source published 2026-07-30. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / BMY
Ask better questions. Keep the evidence.
Explore the available sources for BRISTOL MYERS SQUIBB CO, then keep what deserves another look.
01 Investor activity
Who reports owning BMY?
9 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
02 Business evidence
Reported evidence
What does the company do?
Bristol Myers Squibb discovers, develops, licenses, manufactures, markets, distributes and sells medicines for serious diseases.
Latticework interpretation
What could support the case?
If advanced pipeline candidates become successful commercial medicines, they could expand Bristol Myers Squibb’s product portfolio.
Latticework interpretation
What could break the case?
If regulatory pressures continue to lower prices and reimbursement, Bristol Myers Squibb’s results, cash flow and financial flexibility could be negatively affected.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Bristol Myers Squibb discovers, develops, licenses, manufactures, markets, distributes and sells medicines for serious diseases.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $12,973m | $12,269m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $3,317m | $1,310m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $4,497m | $5,871m |
Comparison caveat: The prior-year quarter includes acquired research-and-development expense for the BioNTech agreement. Net-income improvement is not solely a product-sales or recurring-cost comparison.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If advanced pipeline candidates become successful commercial medicines, they could expand Bristol Myers Squibb’s product portfolio.
Supporting filing ↗The strongest caution
If regulatory pressures continue to lower prices and reimbursement, Bristol Myers Squibb’s results, cash flow and financial flexibility could be negatively affected.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How exposed are key products to IRA price-setting?
Starting evidence: The IRA can reduce prices and reimbursements for certain products, which could significantly affect the business.
Investigate next: Review which marketed products are subject to Medicare price negotiation, and when each price takes effect.
Read the supporting filing ↗Will cost savings be reinvested or offset other pressures?
Starting evidence: A strategic productivity initiative aims to streamline R&D, manufacturing and commercial operations.
Investigate next: Track how restructuring costs and realized savings compare with the stated targets in later filings.
Read the supporting filing ↗Can business development deliver returns?
Starting evidence: BMS views business development as important and recently licensed early-stage oncology, hematology and immunology assets.
Investigate next: Examine the deal terms and clinical stage of these assets, plus any milestone obligations.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.